NO20082288L - Monoklonalt anti-ADDL-antistoff og anvendelse derav - Google Patents
Monoklonalt anti-ADDL-antistoff og anvendelse deravInfo
- Publication number
- NO20082288L NO20082288L NO20082288A NO20082288A NO20082288L NO 20082288 L NO20082288 L NO 20082288L NO 20082288 A NO20082288 A NO 20082288A NO 20082288 A NO20082288 A NO 20082288A NO 20082288 L NO20082288 L NO 20082288L
- Authority
- NO
- Norway
- Prior art keywords
- addl
- types
- antibodies
- disease
- monoclonal anti
- Prior art date
Links
- 102100034004 Gamma-adducin Human genes 0.000 abstract 4
- 101000799011 Homo sapiens Gamma-adducin Proteins 0.000 abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 210000004556 brain Anatomy 0.000 abstract 2
- 239000000284 extract Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 abstract 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2005381125 | 2005-10-21 | ||
| PCT/US2006/040508 WO2007050359A2 (en) | 2005-10-21 | 2006-10-17 | Anti-addl monoclonal antibody and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20082288L true NO20082288L (no) | 2008-05-19 |
Family
ID=39671607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20082288A NO20082288L (no) | 2005-10-21 | 2008-05-19 | Monoklonalt anti-ADDL-antistoff og anvendelse derav |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1940466B1 (enExample) |
| JP (1) | JP5289963B2 (enExample) |
| CN (1) | CN101291692A (enExample) |
| AU (1) | AU2006306553B9 (enExample) |
| CA (1) | CA2626783A1 (enExample) |
| NO (1) | NO20082288L (enExample) |
| RU (1) | RU2008120027A (enExample) |
| WO (1) | WO2007050359A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002003911A2 (en) | 2000-07-07 | 2002-01-17 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| PT1976877E (pt) | 2005-11-30 | 2014-04-29 | Abbvie Inc | Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações |
| CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法 |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US7931899B2 (en) | 2007-05-14 | 2011-04-26 | Medtronic, Inc | Humanized anti-amyloid beta antibodies |
| US8323654B2 (en) | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| PL2170389T3 (pl) * | 2007-06-12 | 2015-03-31 | Ac Immune Sa | Humanizowane przeciwciało przeciw amyloidowi beta |
| ES2445590T3 (es) | 2007-10-05 | 2014-03-04 | Genentech, Inc. | Uso de anticuerpo anti-amiloide beta en enfermedades oculares |
| WO2009070648A2 (en) * | 2007-11-27 | 2009-06-04 | Medtronic, Inc. | Humanized anti-amyloid beta antibodies |
| US9217024B2 (en) | 2007-12-18 | 2015-12-22 | Acumen Pharmaceuticals, Inc. | ADDL receptor polypeptides, polynucleotides and host cells for recombinant production |
| EP2321338A1 (en) * | 2008-08-14 | 2011-05-18 | Merck Sharp & Dohme Corp. | Methods for purifying antibodies using protein a affinity chromatography |
| DK2510359T3 (en) | 2009-12-11 | 2015-12-07 | Araclón Biotech S L | METHODS AND REAGENTS FOR IMPROVED DETECTION OF AMYLOID-BETA PEPTIDES |
| CN104744591B (zh) | 2010-04-15 | 2022-09-27 | Abbvie德国有限责任两合公司 | β淀粉样蛋白结合蛋白 |
| US9320793B2 (en) | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
| ES2573135T3 (es) | 2010-07-14 | 2016-06-06 | Merck Sharp & Dohme Corp. | Anticuerpo monoclonal anti-ADDL y usos del mismo |
| US9176151B2 (en) | 2010-07-14 | 2015-11-03 | Acumen Pharmaceuticals, Inc. | Antibodies, kit and method for detecting amyloid beta oligomers |
| US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| EP2511296A1 (en) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
| US20140302532A1 (en) | 2011-04-12 | 2014-10-09 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
| EP2732289B1 (en) * | 2011-07-13 | 2018-04-11 | Acumen Pharmaceuticals, Inc. | ANTIBODIES, KIT AND in vitro METHOD FOR DETECTING AMYLOID BETA OLIGOMERS |
| JP6231263B2 (ja) * | 2012-07-17 | 2017-11-15 | 株式会社島津製作所 | アフィニティ支持体及びそれを用いた物質の捕捉方法 |
| RS61717B1 (sr) | 2014-07-10 | 2021-05-31 | Bioarctic Ab | Poboljšana antitela koja vezuju a-beta protofibril |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| WO2021055670A1 (en) | 2019-09-20 | 2021-03-25 | Avx Corporation | Somatic cell-based electrical biosensor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994017197A1 (fr) * | 1993-01-25 | 1994-08-04 | Takeda Chemical Industries, Ltd. | ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION |
| US5786180A (en) * | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
| US20030068316A1 (en) * | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
| NZ337765A (en) * | 1997-04-09 | 2001-09-28 | Mindset Biopharmaceuticals Usa | Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease |
| WO2004031400A2 (en) * | 2002-10-01 | 2004-04-15 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
| TWI374893B (en) * | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| NZ554725A (en) * | 2004-10-25 | 2009-10-30 | Merck & Co Inc | Anti-ADDL antibodies and uses thereof |
-
2006
- 2006-10-17 JP JP2008536730A patent/JP5289963B2/ja active Active
- 2006-10-17 CA CA002626783A patent/CA2626783A1/en not_active Abandoned
- 2006-10-17 CN CNA2006800392637A patent/CN101291692A/zh active Pending
- 2006-10-17 AU AU2006306553A patent/AU2006306553B9/en not_active Expired - Fee Related
- 2006-10-17 WO PCT/US2006/040508 patent/WO2007050359A2/en not_active Ceased
- 2006-10-17 EP EP06836346A patent/EP1940466B1/en active Active
- 2006-10-17 RU RU2008120027/13A patent/RU2008120027A/ru not_active Application Discontinuation
-
2008
- 2008-05-19 NO NO20082288A patent/NO20082288L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007050359A3 (en) | 2007-06-21 |
| CA2626783A1 (en) | 2007-05-03 |
| JP2009519895A (ja) | 2009-05-21 |
| WO2007050359A2 (en) | 2007-05-03 |
| EP1940466A4 (en) | 2010-04-07 |
| AU2006306553B9 (en) | 2011-09-29 |
| EP1940466A2 (en) | 2008-07-09 |
| AU2006306553A1 (en) | 2007-05-03 |
| WO2007050359A8 (en) | 2008-05-08 |
| AU2006306553B2 (en) | 2011-08-25 |
| EP1940466B1 (en) | 2012-11-28 |
| CN101291692A (zh) | 2008-10-22 |
| RU2008120027A (ru) | 2009-11-27 |
| JP5289963B2 (ja) | 2013-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20082288L (no) | Monoklonalt anti-ADDL-antistoff og anvendelse derav | |
| NO20072700L (no) | Anti-ADDL antistoffer og anvendelser derav | |
| MX2022005782A (es) | Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos. | |
| MX2009012950A (es) | ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS. | |
| MX2009012949A (es) | Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos. | |
| WO2012045882A3 (en) | Phosphospecific antibodies recognising tau | |
| MX338640B (es) | Anticuerpo monoclonal anti-ligando difundible derivado de amiloide beta y usos de los mismos. | |
| WO2010115843A3 (en) | Pharmaceutical composition | |
| GEP20217222B (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| MX354662B (es) | Anticuerpos fosfoespecificos que reconocen la tau. | |
| EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
| WO2005018424A3 (en) | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits | |
| WO2007062245A3 (en) | Human monoclonal antibody human cd134 (ox40) and methods of making and using same | |
| WO2006099698A3 (en) | Novel anti-plgf antibody | |
| TR201800669T4 (tr) | Alzheimer hastaliğinda tau-aracili patoloji̇ni̇n tanilanmasi ve protei̇n bazli tedavi̇si̇ | |
| AR083819A1 (es) | UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL | |
| DE60336848D1 (de) | Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz | |
| NO20076021L (no) | Antistoffer rettet mot amyloid-betapeptid og metoder som anvender de samme | |
| PH12021552334A1 (en) | Antibodies to pyroglutamate amyloid-ã and uses thereof | |
| NZ596409A (en) | Anti macrophage migration inhibitory factor antibodies | |
| EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
| WO2006014638A3 (en) | ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS | |
| EA200801343A1 (ru) | Иммуноглобулины, направленные против nogo | |
| WO2014159244A3 (en) | O-GlcNAc TAU ANTIBODY AND USE THEREOF | |
| WO2008006087A3 (en) | Antibodies to conformationally trapped proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |